This may explain why most T-ALL cell lines, which typically show Cyclin D3:CDK4/6 complex activation, are less sensitive to sertraline and etoposide as compared to the NKX2–1-positive RPMI-8402 cell line. The gene discussed is CDK4; the disease is acute lymphoblastic leukemia.